AOD-9604

AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH 177-191) studied for fat metabolism and lipolysis research without IGF-1 axis involvement.

AOD-9604, formally known as Anti-Obesity Drug 9604, is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone, spanning residues 177 through 191, with an additional tyrosine residue appended at the N-terminus. This 16-amino acid sequence was specifically isolated from the full-length hGH molecule because early research identified this region as the domain responsible for the lipolytic properties of growth hormone, structurally distinct from the regions driving growth-promoting and diabetogenic effects.

The mechanism of action centers on interaction with beta-3 adrenergic receptors on adipocyte membranes. AOD-9604 stimulates lipolysis — the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol — through activation of hormone-sensitive lipase (HSL) and subsequent lipid mobilization cascades in fat cell research models. Critically, published studies demonstrate that this peptide fragment does not activate the growth hormone receptor (GHR) or stimulate insulin-like growth factor 1 (IGF-1) production, nor does it influence insulin sensitivity or blood glucose levels at research-relevant concentrations. This decoupling of lipolytic activity from the broader GH signaling axis is the primary reason AOD-9604 has attracted sustained interest in metabolic research.

Research applications for AOD-9604 span multiple domains of adipocyte biology and energy metabolism. In vitro studies have demonstrated concentration-dependent stimulation of lipolysis in both murine 3T3-L1 adipocytes and human primary adipocyte cultures. Animal model research has documented effects on fat pad mass reduction, adipocyte size changes, and modulation of lipogenic enzyme expression. Additional research has explored the peptide’s influence on cartilage repair pathways, with published data suggesting chondroprotective properties in joint tissue models — an area of investigation distinct from its metabolic research applications.

AOD-9604 has been the subject of multiple peer-reviewed publications spanning over two decades of metabolic research. The peptide was originally developed at Monash University in Australia by Professor Frank Ng’s laboratory, and has since been studied by research groups internationally. Its well-characterized mechanism and extensive publication history make it a reference compound for studies investigating isolated lipolytic pathways without confounding GH-related effects.

Supplied as a white to off-white lyophilized powder with ≥99% purity confirmed by reverse-phase HPLC and electrospray mass spectrometry (ESI-MS). Each vial is individually sealed under inert atmosphere with a Certificate of Analysis documenting purity, peptide content, amino acid composition, and endotoxin testing. Store at -20°C desiccated and protect from repeated freeze-thaw cycles. Reconstitute with bacteriostatic water or sterile 0.9% sodium chloride prior to experimental use. For laboratory research purposes only. Not for human consumption or clinical use.

Product Specifications

Certificate of Analysis

Every batch ships with a Janoshik-verified COA covering HPLC purity, mass spectrometry confirmation, and batch traceability.

Shipping & Lead Times

• US warehouse: ships within 1–2 business days · estimated 3–5 day delivery
• HK warehouse: ships within 2–3 business days · estimated 7–14 day international delivery
• Carriers: DHL Express, FedEx International, UPS Worldwide
• Discreet outer packaging — no peptide branding visible
• Tracking number emailed on dispatch

Lost or Detained Packages

If your shipment is lost or detained by customs, we will reship once free of charge. Contact us with your order number.